Company profile for Albireo Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our ke...
Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
10 Post Office Square Suite 1000 Boston, MA 02109
Telephone
Telephone
(857) 254-5555
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.ema.europa.eu/en/documents/overview/bylvay-epar-medicine-overview_en.pdf

EMA
05 Jul 2023

https://www.globenewswire.com/news-release/2023/03/02/2619767/0/en/Ipsen-completes-acquisition-of-Albireo-expanding-the-scope-of-its-Rare-Disease-portfolio.html

GLOBENEWSWIRE
02 Mar 2023

https://www.globenewswire.com/news-release/2023/02/22/2612822/0/en/Ipsen-extends-expiration-date-of-tender-offer-for-Albireo-Pharma-Inc-to-1-March-2023.html

GLOBENEWSWIRE
22 Feb 2023

https://www.globenewswire.com/news-release/2023/02/14/2607628/0/en/FDA-Grants-June-15-2023-PDUFA-Date-to-Albireo-for-Bylvay-in-Alagille-Syndrome.html

GLOBENEWSWIRE
14 Feb 2023

https://endpts.com/failed-deal-bidding-war-paved-the-way-for-ipsens-952m-rare-disease-buyout/

Amber Tong ENDPTS
24 Jan 2023

https://www.businesswire.com/news/home/20230108005085/en

BUSINESSWIRE
09 Jan 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Contact Albireo Pharma and get a quotation

Albireo Pharma is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of A4250 DRUG SUBSTANCE AND DRUG PRODUCT bulk offered by Albireo Pharma

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty